Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Sep 10;75(4):702-709.
doi: 10.1093/cid/ciab983.

Retrospective Multicentric Study on Campylobacter spp. Bacteremia in France: The Campylobacteremia Study

Claire Tinévez  1 , Fanny Velardo  2 , Anne Gaëlle Ranc  3 , Damien Dubois  4 , Hélène Pailhoriès  5 , Cyrielle Codde  6 , Olivier Join-Lambert  7 , Emmanuelle Gras  8 , Stéphane Corvec  9 , Catherine Neuwirth  10 , Cléa Melenotte  11 , Marie Dorel  12 , Anne Sophie Lagneaux  13 , Maxime Pichon  14 , Violaine Doat  15 , Damien Fournier  16 , Adrien Lemaignen  17 , Leslie Bouard  18 , Pierre Patoz  19 , Genevieve Hery-Arnaud  20 , Nadine Lemaitre  21 , Célia Couzigou  22 , Thomas Guillard  23 , Elise Recalt  24 , Emmanuelle Bille  25 , Yaniss Belaroussi  2 , Didier Neau  1 , Charles Cazanave  1 , Philippe Lehours  26   27 , Mathilde Puges  1 ; Campylobacteremia study group
Collaborators, Affiliations
Multicenter Study

Retrospective Multicentric Study on Campylobacter spp. Bacteremia in France: The Campylobacteremia Study

Claire Tinévez et al. Clin Infect Dis. .

Abstract

Background: Campylobacter spp. bacteremia is a severe infection. A nationwide 5-year retrospective study was conducted to characterize its clinical features and prognostic factors.

Methods: The study included patients with Campylobacter spp. bacteremia diagnosed in 37 French hospitals participating in the surveillance network of the National Reference Center for Campylobacters and Helicobacters, from 1 January 2015 to 31 December 2019. The goal was to analyze the effects of a delay of appropriate antibiotic therapy and other risk factors on 30-day mortality rates, antibiotic resistance, patient characteristics, and prognosis according to the Campylobacter species.

Results: Among the 592 patients, Campylobacter jejuni and Campylobacter fetus were the most commonly identified species (in 42.9% and 42.6%, respectively). The patients were elderly (median age 68 years), and most had underlying conditions, mainly immunodepression (43.4%), hematologic cancers (25.9%), solid neoplasms (23%), and diabetes (22.3%). C. jejuni and Campylobacter coli were associated with gastrointestinal signs, and C. fetus was associated with secondary localizations. Among the 80 patients (13.5%) with secondary localizations, 12 had endocarditis, 38 vascular, 24 osteoarticular, and 9 ascitic fluid infections. The 30-day mortality rate was 11.7%, and an appropriate antibiotic treatment was independently associated with 30-day survival (odds ratio, 0.47 [95% confidence interval, .24-.93]; P = .03). The median efficient therapy initiation delay was quite short (2 days [interquartile range, 0-4 days]) but it had no significant impact on the 30-day mortality rate (P = .78).

Conclusions: Campylobacter spp. bacteremia mainly occurred in elderly immunocompromised individuals with variable clinical presentations according to the species involved. Appropriate antimicrobial therapy was associated with improved 30-day survival.

Keywords: Campylobacter spp; bacteremia; immunosuppression; zoonosis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. J. L. M. reports personal consulting fees from BioAster for providing scientific advice; reports serving as chairman in a Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse meeting for Menari; and reports payment for the association Robert Debré pour la Recherche Médicale. O. J. L. reports travel support from Pfizer, Astellas, and MSD for European Congress of Clinical Microbiology and Infectious Diseases conventions (2019, 2020, and 2021). M. Pichon. reports receiving a speaker grant (grant RICAI2020) from Pfizer and an educational grant from Merieux University. O. B. reports consulting fees from Viatris, honoraria for educational activities from Pfizer, and travel support from Pfizer, Sanofi, MSD, and Institut Mérieux. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publication types

Substances